Zacks Reiterates Neutral on Allergan (AGN)

By admin | 6 years ago

Allergan (NYSE: AGN)‘s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Friday. They currently have a $98.00 target price on the stock.

Shares of Allergan opened at 92.90 on Friday. Allergan has a 52 week low of $69.40 and a 52 week high of $97.09. The company has a market cap of $28.232 billion and a P/E ratio of 28.66.

Allergan last announced its earnings results on Wednesday, May 2nd. The company reported $0.86 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.87 by $0.01. Allergan’s revenue was up 9.5% compared to the same quarter last year. On average, analysts predict that Allergan will post $1.05 earnings per share next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Allergan to $95.00 in a research note to investors on Thursday. They now have a “hold” rating on the stock. Separately, analysts at Buckingham Research downgraded shares of Allergan from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, May 2nd. Finally, analysts at Bank of America (NYSE: BAC) raised their price target on shares of Allergan from $100.00 to $106.00 in a research note to investors on Tuesday, April 10th.

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.

About the author